Predictive Oncology (NASDAQ:AGPU) Shares Down 13.6% – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:AGPU)’s share price traded down 13.6% during trading on Thursday . The company traded as low as $5.57 and last traded at $5.60. 378,708 shares traded hands during trading, a decline of 92% from the average session volume of 4,758,807 shares. The stock had previously closed at $6.48.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen cut Predictive Oncology to a “strong sell” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Predictive Oncology in a research report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Predictive Oncology Stock Performance

The firm has a market cap of $32.41 million, a P/E ratio of -0.46 and a beta of 3.45. The business’s fifty day moving average price is $3.86.

Predictive Oncology (NASDAQ:AGPU) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.36) EPS for the quarter. The business had revenue of $0.04 million during the quarter.

About Predictive Oncology

Predictive Oncology (NASDAQ: AGPU) is a biotechnology company focused on oncology-related research and product development that combines laboratory science with data analytics. The company positions itself to support precision medicine by applying computational methods and laboratory testing to better understand tumor biology and to accelerate the identification and development of oncology therapeutics and diagnostics.

Its activities include laboratory-based testing and analytic services intended to inform drug discovery and development, biomarker identification, and patient stratification efforts.